Home » Stocks » Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. (CBMG)

Stock Price: $18.40 USD -0.02 (-0.11%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 357.89M
Revenue (ttm) 290,655
Net Income (ttm) -53.63M
Shares Out 19.45M
EPS (ttm) -2.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $18.40
Previous Close $18.42
Change ($) -0.02
Change (%) -0.11%
Day's Open 18.41
Day's Range 18.30 - 18.44
Day's Volume 47,637
52-Week Range 11.48 - 19.50

More Stats

Market Cap 357.89M
Enterprise Value 363.78M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.45M
Float 11.46M
EPS (basic) -2.77
EPS (diluted) -2.78
FCF / Share -2.62
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 378,284
Short Ratio 4.29
Short % of Float 3.30%
Beta 1.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,231.31
PB Ratio 11.00
Revenue 290,655
Operating Income -54.09M
Net Income -53.63M
Free Cash Flow -50.73M
Net Cash -5.89M
Net Cash / Share -0.30
Gross Margin 95.49%
Operating Margin -18,609.08%
Profit Margin -18,451.50%
FCF Margin -17,454.30%
ROA -34.47%
ROE -93.51%
ROIC -139.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$19.00*
Low
19.0
Current: $18.40
High
19.0
Target: 19.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue0.340.220.340.632.510.560.200.270.04
Revenue Growth51.48%-33.38%-46.36%-74.94%343.93%175.42%-25.11%670.76%-
Gross Profit0.280.090.17-0.230.630.32-0.090.080.04
Operating Income-50.99-40.51-27.58-28.42-20.85-12.44-11.35-7.06-1.29
Net Income-49.98-38.95-25.49-28.21-19.45-15.47-13.80-7.03-0.77
Shares Outstanding18.9817.7414.3513.5111.478.635.793.131.52
Earnings Per Share-2.63-2.20-1.78-2.09-1.70-1.79-2.38-2.24-0.50
Operating Cash Flow-39.65-25.11-18.59-15.87-11.75-9.72-8.46-7.460.35
Capital Expenditures-10.53-6.59-10.17-2.68-1.87-0.31-0.15-1.08-
Free Cash Flow-50.18-31.70-28.76-18.54-13.63-10.03-8.60-8.540.35
Cash & Equivalents32.4452.8121.5739.2514.8814.777.184.140.60
Total Debt14.33----0.040.07-0.12
Net Cash / Debt18.1152.8121.5739.2514.8814.737.114.140.49
Assets97.3210861.1668.6349.4643.6917.606.751.65
Liabilities41.6122.363.862.733.104.532.200.601.97
Book Value55.7285.2257.3065.8946.3639.1615.406.16-0.33
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cellular Biomedicine Group, Inc.
Country United States
Employees 217
CEO Bi Zuo Liu

Stock Information

Ticker Symbol CBMG
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CBMG

Description

Cellular Biomedicine Group, a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.